에 대한 최신 뉴스 Tenet Healthcare (NYSE:THC) 주식

Tenet Healthcare

Tenet Healthcare is a Dallas-based healthcare services organization. It operates a collection of hospitals (about 50 as of July 2024) and over 500 ambulatory surgery centers and other outpatient facilities across the U.S., primarily in the South. Through its Conifer segment, Tenet also provides revenue cycle management solutions.

Large Cap

News

Movers

Trading Ideas

BABA

INCY

INTU

Citigourp Global Markets 2% Protected Notes Linked To The Djia

ULTA

지난 주 가장 성적이 저조했던 대형주들입니다. 당신의 포트폴리오에 포함되어 있나요?1. 타깃 코퍼레이션(NYSE:TGT)의 주식은 회사가 3분기 실적을 발표했으나 예상에 미치지 못하고, 애널리스트들이 주가 목표를 하향 조정한 후 17.83% 하락했다.

타깃, 알리바바 및 테무는 지난주 최악의 성과를 보인 10개 대형주 중 일부 (11월 18일 ~ 11월 22일)

ICLR

이들 10개 대형주는 지난주 최악의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요? 1. 아이콘(NASDAQ:ICLR)의 주식은 예상보다 저조한 실적을 발표한 후 25.95% 급락했다. 여러 애널리스트들도 주가 목표를 하향 조정했다.

제뉴인 파츠 및 탑빌드가 지난주 최악의 성과를 보인 10개 대형주 중 일부 (10월 21일-10월 25일)

AVTR

CBRE

ENPH

FCNCA

LPLA

MANH

SIRI

SPOT

이들 11개 대형주는 지난주 최고의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요? QXO(NASDAQ:QXO)의 주가는 사모 금융 유치를 발표한 이후 33.37% 상승했다.

유니버셜 헬스 및 록히드 마틴은 지난주 최고 성과를 보여준 11개 대형주 중 일부 (7월 21일-7월 27일)

Tenet Healthcare Corporation Common Stock

Tenet Healthcare Corp

THC BIOMED INTL LTD ORD by THC BioMed Intl Ltd.

THC Biomed International Ltd

TH International Limited - Ordinary shares

TH International Ltd

THUNDER BRDG CAP PARTNERS IV INC CL A

THUNDER BRDG CAP PARTNERS IV INC UNIT 1 CL A & 1/5 WT EXP

THUNDER BRDG CAP PARTNERS IV INC WT EXP

THC THERAPEUTICS INC by THC Therapeutics, Inc.

THC Therapeutics Inc

Spinnaker ETF Series Cannabis ETF

Tenet Healthcare's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THC#NYSE">THC</a>) short percent of float has risen 33.42% since its last report. The company recently reported that it has 3.58 million shares sold short, which is 4.95% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.18 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Tenet Healthcare Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1736883015_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Tenet Healthcare has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Tenet Healthcare's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Tenet Healthcare's peer group average for short interest as a percentage of float is 5.24%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

(THC) - Analyzing Tenet Healthcare's Short Interest

Tenet Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THC#NYSE">THC</a>) has outperformed the market over the past 5 years by 16.42% on an annualized basis producing an average annual return of 28.9%. Currently, Tenet Healthcare has a market capitalization of $12.36 billion. 
Buying $1000 In THC: If an investor had bought $1000 of THC stock 5 years ago, it would be worth $3,566.42 today based on a price of $130.00 for THC at the time of writing.
<h3>Tenet Healthcare's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1736434812_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $1000 Invested In Tenet Healthcare 5 Years Ago Would Be Worth Today

16 analysts have shared their evaluations of Tenet Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THC#NYSE">THC</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">5</td>
<td align="right">9</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">4</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $184.56, with a high estimate of $217.00 and a low estimate of $140.00. A 0.2% drop is evident in the current average compared to the previous average price target of $184.93. 
<img src="https://www.benzinga.com/files/images/story/2025/1736272841_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
The analysis of recent analyst actions sheds light on the perception of Tenet Healthcare by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tim Rezvan</td>
<td>Keybanc</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$185.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>David Macdonald</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$175.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Benjamin Rossi</td>
<td>JP Morgan</td>
<td>Announces</td>
<td>Overweight</td>
<td>$175.00</td>
<td>-</td>
</tr>
<tr>
<td>Jamie Perse</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$140.00</td>
<td>$196.00</td>
</tr>
<tr>
<td>Stephen Baxter</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$150.00</td>
<td>$205.00</td>
</tr>
<tr>
<td>John Ransom</td>
<td>Raymond James</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$195.00</td>
<td>$195.00</td>
</tr>
<tr>
<td>Andrew Mok</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$190.00</td>
<td>$171.00</td>
</tr>
<tr>
<td>Stephen Baxter</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$205.00</td>
<td>$195.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Raises</td>
<td>Overweight</td>
<td>$177.00</td>
<td>$168.00</td>
</tr>
<tr>
<td>Jamie Perse</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$196.00</td>
<td>$173.00</td>
</tr>
<tr>
<td>Ben Hendrix</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$183.00</td>
<td>$174.00</td>
</tr>
<tr>
<td>David Macdonald</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$190.00</td>
<td>$180.00</td>
</tr>
<tr>
<td>A.J. Rice</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$217.00</td>
<td>$197.00</td>
</tr>
<tr>
<td>Stephen Baxter</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$195.00</td>
<td>$175.00</td>
</tr>
<tr>
<td>David Macdonald</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$180.00</td>
<td>$170.00</td>
</tr>
<tr>
<td>Matthew Gillmor</td>
<td>Keybanc</td>
<td>Announces</td>
<td>Overweight</td>
<td>$200.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Tenet Healthcare. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Tenet Healthcare compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Tenet Healthcare's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Tenet Healthcare's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/THC/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Tenet Healthcare analyst ratings.</a>
<h2>Discovering Tenet Healthcare: A Closer Look</h2>
Tenet Healthcare is a Dallas-based healthcare services organization. It operates a collection of hospitals (about 50 as of July 2024) and over 500 ambulatory surgery centers and other outpatient facilities across the U.S., primarily in the South. Through its Conifer segment, Tenet also provides revenue cycle management solutions.
<h3>Tenet Healthcare's Financial Performance</h3>
Market Capitalization: Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.
Revenue Growth: Tenet Healthcare displayed positive results in 3 months. As of 30 September, 2024, the company achieved a solid revenue growth rate of approximately 1.11%. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Tenet Healthcare's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 9.22%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 12.92%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Tenet Healthcare's ROA stands out, surpassing industry averages. With an impressive ROA of 1.61%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: With a below-average debt-to-equity ratio of 3.36, Tenet Healthcare adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

Breaking Down Tenet Healthcare: 16 Analysts Share Their Views

Keybanc analyst Tim Rezvan maintains Tenet Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THC#NYSE">THC</a>) with a Overweight and lowers the price target from $200 to $185.

Price Target

Keybanc Maintains Overweight on Tenet Healthcare, Lowers Price Target to $185

Truist Securities analyst David Macdonald maintains Tenet Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THC#NYSE">THC</a>) with a Buy and lowers the price target from $190 to $175.

Truist Securities Maintains Buy on Tenet Healthcare, Lowers Price Target to $175

Tenet Healthcare's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THC#NYSE">THC</a>) short percent of float has risen 17.07% since its last report. The company recently reported that it has 2.43 million shares sold short, which is 3.36% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.62 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Tenet Healthcare Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734699614_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Tenet Healthcare has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Tenet Healthcare's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Tenet Healthcare's peer group average for short interest as a percentage of float is 4.82%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Peering Into Tenet Healthcare's Recent Short Interest

JP Morgan analyst Benjamin Rossi assumes Tenet Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THC#NYSE">THC</a>) with a Overweight rating and announces Price Target of $175.

Initiation

JP Morgan Assumes Tenet Healthcare at Overweight, Announces Price Target of $175

15 analysts have shared their evaluations of Tenet Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THC#NYSE">THC</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">9</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">3</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $183.6, along with a high estimate of $217.00 and a low estimate of $140.00. This upward trend is apparent, with the current average reflecting a 1.4% increase from the previous average price target of $181.07.
<img src="https://www.benzinga.com/files/images/story/2024/1734379250_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Tenet Healthcare. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jamie Perse</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$140.00</td>
<td>$196.00</td>
</tr>
<tr>
<td>Stephen Baxter</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$150.00</td>
<td>$205.00</td>
</tr>
<tr>
<td>John Ransom</td>
<td>Raymond James</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$195.00</td>
<td>$195.00</td>
</tr>
<tr>
<td>Andrew Mok</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$190.00</td>
<td>$171.00</td>
</tr>
<tr>
<td>Stephen Baxter</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$205.00</td>
<td>$195.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Raises</td>
<td>Overweight</td>
<td>$177.00</td>
<td>$168.00</td>
</tr>
<tr>
<td>Jamie Perse</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$196.00</td>
<td>$173.00</td>
</tr>
<tr>
<td>Ben Hendrix</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$183.00</td>
<td>$174.00</td>
</tr>
<tr>
<td>David Macdonald</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$190.00</td>
<td>$180.00</td>
</tr>
<tr>
<td>A.J. Rice</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$217.00</td>
<td>$197.00</td>
</tr>
<tr>
<td>Stephen Baxter</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$195.00</td>
<td>$175.00</td>
</tr>
<tr>
<td>David Macdonald</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$180.00</td>
<td>$170.00</td>
</tr>
<tr>
<td>Matthew Gillmor</td>
<td>Keybanc</td>
<td>Announces</td>
<td>Overweight</td>
<td>$200.00</td>
<td>-</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$168.00</td>
<td>$168.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$168.00</td>
<td>$168.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Tenet Healthcare. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Tenet Healthcare compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Tenet Healthcare's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Tenet Healthcare's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/THC/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Tenet Healthcare analyst ratings.</a>
<h2>Delving into Tenet Healthcare's Background</h2>
Tenet Healthcare is a Dallas-based healthcare services organization. It operates a collection of hospitals (about 50 as of July 2024) and over 500 ambulatory surgery centers and other outpatient facilities across the U.S., primarily in the South. Through its Conifer segment, Tenet also provides revenue cycle management solutions.
<h3>Unraveling the Financial Story of Tenet Healthcare</h3>
Market Capitalization: Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.
Revenue Growth: Over the 3 months period, Tenet Healthcare showcased positive performance, achieving a revenue growth rate of 1.11% as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Tenet Healthcare's net margin is impressive, surpassing industry averages. With a net margin of 9.22%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Tenet Healthcare's ROE excels beyond industry benchmarks, reaching 12.92%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Tenet Healthcare's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 1.61% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Tenet Healthcare's debt-to-equity ratio is below the industry average at 3.36, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>Analyst Ratings: What Are They?</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Expectations For Tenet Healthcare's Future

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>B of A Securities analyst Adam Angelov downgraded the rating for Logitech International S.A. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LOGI#NASDAQ">LOGI</a>) from Buy to Neutral and lowered the price target from $114 to $92. Logitech shares closed at $84.39 on Friday. See how other analysts view this stock.</li>
<li>Mizuho analyst William Janela downgraded Northern Oil and Gas, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOG#NYSE">NOG</a>) from Outperform to Neutral and maintained the price target of $47. Northern Oil &amp; Gas shares closed at $40.71 on Friday. <a href="https://www.benzinga.com/quote/NOG/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Exane BNP Paribas analyst Andrew Grobler downgraded the rating for Robert Half Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RHI#NYSE">RHI</a>) from Outperform to Underperform and announced a $64 price target. Robert Half shares closed at $76.10 on Friday. See how other analysts view this stock.</li>
<li>Goldman Sachs analyst Jamie Perse downgraded Tenet Healthcare Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THC#NYSE">THC</a>) from Buy to Neutral and lowered the price target from $196 to $140. Tenet Healthcare shares closed at $136.71 on Friday. <a href="https://www.benzinga.com/quote/THC/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Jefferies analyst Philippe Houchois downgraded Ford Motor Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/F#NYSE">F</a>) from Hold to Underperform and slashed the price target from $12 to $9. Ford shares closed at $10.39 on Friday. <a href="https://www.benzinga.com/quote/F/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying Ford stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="612" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/16071010/image-124-1024x612.png" alt="" class="wp-image-693633" style="width:631px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/16071010/image-124-1024x612.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/16071010/image-124-300x179.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/16071010/image-124-768x459.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/16071010/image-124.png 1123w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/24/12/42482639/wall-streets-most-accurate-analysts-give-their-take-on-3-energy-stocks-with-over-6-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Energy Stocks With Over 6% Dividend Yields</a></li>
</ul>

Downgrades

Markets

LOGI

This Ford Analyst Turns Bearish; Here Are Top 5 Downgrades For Monday

Goldman Sachs analyst Jamie Perse downgrades Tenet Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THC#NYSE">THC</a>) from Buy to Neutral and lowers the price target from $196 to $140.

Goldman Sachs Downgrades Tenet Healthcare to Neutral, Lowers Price Target to $140

Tenet Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THC#NYSE">THC</a>) has outperformed the market over the past 5 years by 15.95% on an annualized basis producing an average annual return of 29.64%. Currently, Tenet Healthcare has a market capitalization of $13.22 billion. 
Buying $100 In THC: If an investor had bought $100 of THC stock 5 years ago, it would be worth $363.77 today based on a price of $139.00 for THC at the time of writing.
<h3>Tenet Healthcare's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1733934626_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning Tenet Healthcare Stock In The Last 5 Years

Tenet Healthcare's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THC#NYSE">THC</a>) short percent of float has fallen 13.81% since its last report. The company recently reported that it has 2.08 million shares sold short, which is 2.87% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.49 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Tenet Healthcare Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732901410_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Tenet Healthcare has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Tenet Healthcare's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Tenet Healthcare's peer group average for short interest as a percentage of float is 4.10%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

General

Tenet Healthcare shares are trading lower. The stock may be moving on continued weakness following a Wells Fargo ratings downgrade and price target cut on Monday.

Wells Fargo analyst Stephen Baxter downgrades Tenet Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THC#NYSE">THC</a>) from Overweight to Equal-Weight and lowers the price target from $205 to $150.

Wells Fargo Downgrades Tenet Healthcare to Equal-Weight, Lowers Price Target to $150

These large-cap stocks were the worst performers in the last week. Are they in your portfolio?
<ol start="1">
<li>Target Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TGT#NYSE">TGT</a>) tumbled 17.83% after the company reported the third-quarter earnings miss, and analysts slashed the <a href="https://www.benzinga.com/node/42117500" target="_blank" rel="noreferrer noopener">price target on the stock</a>.</li>
<li>Temu parent PDD Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDD#NASDAQ">PDD</a>) plummeted 12.22% after the company reported <a href="https://www.benzinga.com/node/42111158" target="_blank" rel="noreferrer noopener">worse-than-expected financial results</a>. Analysts cut <a href="https://www.benzinga.com/quote/pdd/analyst-ratings" target="_blank" rel="noreferrer noopener">the price forecast on the stock</a>.</li>
<li>ZTO Express (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZTO#NYSE">ZTO</a>) stock fell 8.50% after the company reported third-quarter results and cut its FY24 <a href="https://www.benzinga.com/node/42076268" target="_blank" rel="noreferrer noopener">guidance for parcel volume</a>.</li>
<li>Tenet Healthcare Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THC#NYSE">THC</a>) stock dipped 7.54% after Raymond James downgraded the stock <a href="https://www.benzinga.com/quote/thc/analyst-ratings" target="_blank" rel="noreferrer noopener">from Strong Buy to Outperform</a>.</li>
<li>Ulta Beauty, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ULTA#NASDAQ">ULTA</a>) fell 7.34% after Berkshire Hathaway <a href="https://www.benzinga.com/node/42013172">cut its position</a> in the stock.</li>
<li>Intuit Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTU#NASDAQ">INTU</a>) declined 6.94% after the company <a href="https://www.benzinga.com/node/42123997" target="_blank" rel="noreferrer noopener">reported second-quarter results</a>. Several analysts revised <a href="https://www.benzinga.com/quote/intu/analyst-ratings" target="_blank" rel="noreferrer noopener">the price forecasts on the stock</a>.</li>
<li>Nokia Corporation NYSE: NOK) stock decreased 6.28%. The company secured a multi-year, multi-billion USD contract extension <a href="https://www.benzinga.com/node/42089876" target="_blank" rel="noreferrer noopener">with </a><a href="https://www.benzinga.com/node/42089876" target="_blank" rel="noreferrer noopener">Bharti Airtel</a><a href="https://www.benzinga.com/node/42089876" target="_blank" rel="noreferrer noopener"> in India</a>.</li>
<li>Alibaba Group Holding Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABA#NYSE">BABA</a>) shares were down 6.16%. The company plans to issue U.S. dollars and Chinese yuan bonds to raise capital, repay existing debt, and support <a href="https://www.benzinga.com/node/42032495" target="_blank" rel="noreferrer noopener">an ongoing stock buyback initiative</a>.</li>
<li>Banco Santander (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SAN#NYSE">SAN</a>) stock dipped 5.60%.</li>
<li>Incyte Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INCY#NASDAQ">INCY</a>) stock declined 5.47% after the company announced that data from its Phase 2 study evaluating MRGPRX4 (INCB000547) in cholestatic does not <a href="https://www.benzinga.com/node/42070590" target="_blank" rel="noreferrer noopener">support further development</a>.</li>
</ol>
Photo via Shutterstock

Target, Alibaba And Temu Parent PDD Are Among Top 10 Large-Cap Losers Last Week (Nov 18-Nov 22): Are The Others In Your Portfolio?

Across the recent three months, 13 analysts have shared their insights on Tenet Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THC#NYSE">THC</a>), expressing a variety of opinions spanning from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">9</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">3</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Tenet Healthcare and provided 12-month price targets. The average target is $189.54, accompanied by a high estimate of $217.00 and a low estimate of $168.00. Marking an increase of 6.58%, the current average surpasses the previous average price target of $177.83. 
<img src="https://www.benzinga.com/files/images/story/2024/1732287634_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
A clear picture of Tenet Healthcare's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>John Ransom</td>
<td>Raymond James</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$195.00</td>
<td>$195.00</td>
</tr>
<tr>
<td>Andrew Mok</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$190.00</td>
<td>$171.00</td>
</tr>
<tr>
<td>Stephen Baxter</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$205.00</td>
<td>$195.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Raises</td>
<td>Overweight</td>
<td>$177.00</td>
<td>$168.00</td>
</tr>
<tr>
<td>Jamie Perse</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$196.00</td>
<td>$173.00</td>
</tr>
<tr>
<td>Ben Hendrix</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$183.00</td>
<td>$174.00</td>
</tr>
<tr>
<td>David Macdonald</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$190.00</td>
<td>$180.00</td>
</tr>
<tr>
<td>A.J. Rice</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$217.00</td>
<td>$197.00</td>
</tr>
<tr>
<td>Stephen Baxter</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$195.00</td>
<td>$175.00</td>
</tr>
<tr>
<td>David Macdonald</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$180.00</td>
<td>$170.00</td>
</tr>
<tr>
<td>Matthew Gillmor</td>
<td>Keybanc</td>
<td>Announces</td>
<td>Overweight</td>
<td>$200.00</td>
<td>-</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$168.00</td>
<td>$168.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$168.00</td>
<td>$168.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Tenet Healthcare. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Tenet Healthcare compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Tenet Healthcare's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Capture valuable insights into Tenet Healthcare's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/THC/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Tenet Healthcare analyst ratings.</a>
<h2>Delving into Tenet Healthcare's Background</h2>
Tenet Healthcare is a Dallas-based healthcare services organization. It operates a collection of hospitals (about 50 as of July 2024) and over 500 ambulatory surgery centers and other outpatient facilities across the U.S., primarily in the South. Through its Conifer segment, Tenet also provides revenue cycle management solutions.
<h3>Key Indicators: Tenet Healthcare's Financial Health</h3>
Market Capitalization: Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.
Revenue Growth: Tenet Healthcare's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2024, the company achieved a revenue growth rate of approximately 1.11%. This indicates a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Tenet Healthcare's net margin excels beyond industry benchmarks, reaching 9.22%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Tenet Healthcare's ROE stands out, surpassing industry averages. With an impressive ROE of 12.92%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Tenet Healthcare's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 1.61% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Tenet Healthcare's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 3.36.
<h2>The Basics of Analyst Ratings</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Demystifying Tenet Healthcare: Insights From 13 Analyst Reviews

WIIM

Tenet Healthcare shares are trading lower after Raymond James downgraded the stock from Strong Buy to Outperform.

Raymond James analyst John Ransom downgrades Tenet Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THC#NYSE">THC</a>) from Strong Buy to Outperform and maintains the price target from $195 to $195.

Raymond James Downgrades Tenet Healthcare to Outperform, Maintains Price Target to $195

Raymond James analyst John Ransom downgrades Tenet Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THC#NYSE">THC</a>) from Strong Buy to Outperform and announces $195 price target.

Raymond James Downgrades Tenet Healthcare to Outperform, Announces $195 Price Target

Deep-pocketed investors have adopted a bearish approach towards Tenet Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THC#NYSE">THC</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in THC usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 11 extraordinary options activities for Tenet Healthcare. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 36% leaning bullish and 54% bearish. Among these notable options, 2 are puts, totaling $50,501, and 9 are calls, amounting to $2,559,675.
<h3>What's The Price Target?</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $80.0 to $170.0 for Tenet Healthcare over the recent three months. 
<h3>Volume &amp; Open Interest Trends</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for Tenet Healthcare's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Tenet Healthcare's whale activity within a strike price range from $80.0 to $170.0 in the last 30 days. 
<h3>Tenet Healthcare Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732216007_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>THC</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$68.0</td>
<td>$68.0</td>
<td>$68.0</td>
<td>$80.00</td>
<td>$550.8K</td>
<td align="right">8</td>
<td align="right">270</td>
</tr>
<tr>
<td>THC</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$68.1</td>
<td>$68.0</td>
<td>$68.0</td>
<td>$80.00</td>
<td>$530.4K</td>
<td align="right">8</td>
<td align="right">288</td>
</tr>
<tr>
<td>THC</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$67.1</td>
<td>$67.1</td>
<td>$67.1</td>
<td>$80.00</td>
<td>$503.2K</td>
<td align="right">8</td>
<td align="right">96</td>
</tr>
<tr>
<td>THC</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$67.7</td>
<td>$67.6</td>
<td>$67.6</td>
<td>$80.00</td>
<td>$471.1K</td>
<td align="right">8</td>
<td align="right">186</td>
</tr>
<tr>
<td>THC</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$68.1</td>
<td>$68.0</td>
<td>$68.0</td>
<td>$80.00</td>
<td>$122.4K</td>
<td align="right">8</td>
<td align="right">487</td>
</tr>
</tbody>
</table>

<h3>About Tenet Healthcare</h3>
Tenet Healthcare is a Dallas-based healthcare services organization. It operates a collection of hospitals (about 50 as of July 2024) and over 500 ambulatory surgery centers and other outpatient facilities across the U.S., primarily in the South. Through its Conifer segment, Tenet also provides revenue cycle management solutions.
Following our analysis of the options activities associated with Tenet Healthcare, we pivot to a closer look at the company's own performance.
<h3>Present Market Standing of Tenet Healthcare</h3>
<ul>
<li>Currently trading with a volume of 1,180,448, the THC's price is down by -2.04%, now at $148.74. </li>
<li>RSI readings suggest the stock is currently is currently neutral between overbought and oversold.</li>
<li>Anticipated earnings release is in 77 days.</li>
</ul>
<h3>What The Experts Say On Tenet Healthcare</h3>
A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $197.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Barclays persists with their Overweight rating on Tenet Healthcare, maintaining a target price of $190. 
&#x2A; An analyst from Wells Fargo has decided to maintain their Overweight rating on Tenet Healthcare, which currently sits at a price target of $205. 
&#x2A; An analyst from Goldman Sachs has decided to maintain their Buy rating on Tenet Healthcare, which currently sits at a price target of $196. 
&#x2A; Maintaining their stance, an analyst from UBS continues to hold a Buy rating for Tenet Healthcare, targeting a price of $217. 
&#x2A; An analyst from Cantor Fitzgerald has decided to maintain their Overweight rating on Tenet Healthcare, which currently sits at a price target of $177. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Tenet Healthcare with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Options

Check Out What Whales Are Doing With THC

In a report released today, Joanna Gajuk from Bank of America Securities maintained a Buy rating on Tenet Healthcare (THC – Research Report). The c...

Bank of America Securities Sticks to Its Buy Rating for Tenet Healthcare (THC)

IHF: Healthcare Dashboard For December

U.S. healthcare spending climbs 7.5% in 2023

Tenet Healthcare Stock: An Improved Option Here (Rating Upgrade)

U.S. healthcare execs turn more bullish for 2025: Deloitte

Truist analyst David MacDonald lowered the firm's price target on Tenet Healthcare (THC) to $175 from $190 and keeps a Buy rating on the shares as ...

Tenet Healthcare price target lowered to $175 from $190 at Truist

KeyBanc analyst Matthew Gillmor lowered the firm's price target on Tenet Healthcare (THC) to $185 from $200 and keeps an Overweight rating on the s...

Tenet Healthcare price target lowered to $185 from $200 at KeyBanc

Catch up on the top industries and stocks that were impacted, or were predicted to be impacted, by the comments, actions and policies of President-...

Trump Trade: EV 'battery belt' towns betting Trump won't remove subsidies

We introduce the ValuEngine Top Ten Stocks to Watch in 2025 list. We also provide a recap and performance analysis for the list published last January as Ten Stocks to Watch in 2024.

Top Ten Stocks To Watch In 2025

ValuEngine's Top 10 Stocks For 2025

AAPL

ACHC

AFRM

ARRY

BHPLF

CHWY

CNMD

COLL

CRDO

CVNA

DKNG

DOCU

FSLR

FTCI

GEHC

HNDAF

HRMY

HYMLF

HYMTF

ISRG

LFST

LNTH

MAXN

OKTA

PYPL

ROKU

SCCO

SEDG

SGRY

SHLS

STLD

TSLA

TWLO

VALE

VEEV

Press Releases

Tenet to Report its Second Quarter 2024 Results on July 24th

Tenet Reports Strong Second Quarter 2024 Results; Raises 2024 Financial Outlook

Tenet Healthcare to Sell Five Birmingham Hospitals to Orlando Health

Tenet to Participate in the 2024 Wells Fargo Healthcare Conference

Tenet Completes Sale of Five Hospitals in Birmingham

Tenet to Report its Third Quarter 2024 Results on October 29th

Tenet to Participate in the UBS Global Healthcare Conference

Tenet Reports Strong Third Quarter 2024 Results; Raises 2024 Financial Outlook

Health Care

Commure to Deploy Ambient AI Platform to Tenet Physician Resources for Enhanced Clinical Workflows

Tenet to Report its Fourth Quarter 2024 Results on February 12th

Acadia Healthcare Company, Inc. - Common Stock

Acadia Healthcare Co

Ardent Health Partners, Inc. Common Stock

Ardent Health Partners

Auna

IMAC Hldgs

Brookdale Senior Living Inc. Common Stock

Brookdale Senior Living

Concentra Group Holdings Parent, Inc. Common Stock

Concentra Group Holdings

Community Health Systems, Inc. Common Stock

Community Health Sys

Encompass Health Corporation Common Stock

Encompass Health

Ensign Group

HCA Healthcare

Inspire Veterinary Partners, Inc. - Class A Common Stock

Inspire Veterinary

Joint

National HealthCare Corporation Common Stock

National Healthcare

PACS Group

Regional Health Properties, Inc. Common Stock

Regional Health Props

Select Medical Holdings Corporation Common Stock

Select Medical Hldgs

Surgery Partners

Sonida Senior Living

SunLink Health Systems, Inc. Common Stock

SunLink Health Systems

The Oncology Institute, Inc. - Common Stock

Oncology Institute

Universal Health Services, Inc. Common Stock

Universal Health Servs

US Physical Therapy

Keybanc

Truist Securities

JP Morgan

Goldman Sachs

Wells Fargo

지난 주 가장 성적이 저조했던 대형주들입니다. 당신의 포트폴리오에 포함되어 있나요?
1. 타깃 코퍼레이션(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TGT#NYSE">TGT</a>)의 주식은 회사가 3분기 실적을 발표했으나 예상에 미치지 못하고, 애널리스트들이 <a href="https://www.benzinga.com/node/42117500" target="_blank" rel="noreferrer noopener">주가 목표를 하향 조정</a>한 후 17.83% 하락했다.
2. 테무의 모회사인 PDD 홀딩스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDD#NASDAQ">PDD</a>)의 주식은 회사가 <a href="https://www.benzinga.com/node/42111158" target="_blank" rel="noreferrer noopener">예상보다 저조한 재무결과</a>를 발표하고 애널리스트들이 <a href="https://www.benzinga.com/quote/pdd/analyst-ratings" target="_blank" rel="noreferrer noopener">주가 전망을 하향 조정</a>한 후 12.22% 급락했다.
3. ZTO 익스프레스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZTO#NYSE">ZTO</a>)의 주식은 회사가 3분기 실적을 발표하고 FY24 <a href="https://www.benzinga.com/node/42076268" target="_blank" rel="noreferrer noopener">소포 물량 가이던스를 하향 조정</a>한 후 8.50% 하락했다.
4. 테넷 헬스케어(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THC#NYSE">THC</a>)의 주식은 투자은행 레이먼드 제임스(Raymond James)가 주식을 <a href="https://www.benzinga.com/quote/thc/analyst-ratings" target="_blank" rel="noreferrer noopener">강력 매수에서 아웃퍼폼으로 하향 조정</a>한 후 7.54% 하락했다.
5. 울타 뷰티(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ULTA#NASDAQ">ULTA</a>)의 주식은 버크셔 해서웨이가 <a href="https://www.benzinga.com/node/42013172">주식 보유 비중을 축소</a>한 후 7.34% 하락했다.
6. 인튜이트(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTU#NASDAQ">INTU</a>)의 주식은 회사가 <a href="https://www.benzinga.com/node/42123997" target="_blank" rel="noreferrer noopener">2분기 실적을 발표</a>한 후 여러 애널리스트들이 <a href="https://www.benzinga.com/quote/intu/analyst-ratings" target="_blank" rel="noreferrer noopener">주가 전망을 수정</a>하여 6.94% 하락했다.
7. 노키아 코퍼레이션 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOK#NYSE">NOK</a>)의 주식은 회사가 바티 에어텔(<a href="https://www.benzinga.com/node/42089876" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">Bharti Airtel</a>)과 인도에서 수년간 수십억 달러 규모의 계약 연장을 확보했다고 발표한 후 6.28% 하락했다.
8. 알리바바 그룹 홀딩(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABA#NYSE">BABA</a>)의 주식은 회사가 자본을 조달하고 기존 부채를 상환하며 <a href="https://www.benzinga.com/node/42032495" target="_blank" rel="noreferrer noopener">진행 중인 자사주 매입 프로그램</a>을 지원하기 위해 미국 달러 및 중국 위안화 채권을 발행할 계획이라고 발표한 후 6.16% 하락했다.
9. 방코 산탄데르(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SAN#NYSE">SAN</a>)의 주식은 5.60% 하락했다.
10. 인사이트(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INCY#NASDAQ">INCY</a>)의 주식은 회사가 MRGPRX4 (INCB000547)에 대한 2상 연구 데이터를 발표하고 <a href="https://www.benzinga.com/node/42070590" target="_blank" rel="noreferrer noopener">추가 개발을 지원하지 않는다고 발표</a>한 후 5.47% 하락했다.
사진 출처: Shutterstock
다음 읽기: <a href="https://kr.benzinga.com/news/usa/stocks/%EC%8A%88%ED%8D%BC-%EB%A7%88%EC%9D%B4%ED%81%AC%EB%A1%9C-%EB%B0%8F-%EC%8B%AC%EB%B3%B4%ED%8B%B1-%EC%A7%80%EB%82%9C%EC%A3%BC-%EC%B5%9C%EA%B3%A0-%EC%84%B1%EA%B3%BC%EB%A5%BC-%EB%B3%B4%EC%97%AC%EC%A4%80-10/" target="_blank" rel="noopener">슈퍼 마이크로 및 심보틱 지난주 최고 성과를 보여준 10개 대형주 중 일부 (11월 18일 – 11월 22일)</a>
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

이들 10개 대형주는 지난주 최악의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요?
1. 아이콘(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICLR#NASDAQ">ICLR</a>)의 주식은 <a href="https://www.benzinga.com//node/41500867" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">예상보다 저조한 실적</a>을 발표한 후 25.95% 급락했다. 여러 애널리스트들도 <a href="https://www.benzinga.com/quote/iclr/analyst-ratings" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">주가 목표</a>를 하향 조정했다.
2. 제뉴인 파츠(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GPC#NYSE">GPC</a>)의 주식은 엇갈린 3분기 실적과 <a href="https://www.benzinga.com//node/41455012" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">예상보다 낮은 2024년 EPS</a>를 발표한 후 20.21% 하락했다. 여러 애널리스트들이 <a href="https://www.benzinga.com/quote/gpc/analyst-ratings" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">주가 목표</a>를 하향 조정했다.
3. 뉴몬트(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NEM#NYSE">NEM</a>)의 주식은 <a href="https://www.benzinga.com//node/41503948" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">3분기 재무 실적</a>을 발표한 후 15.97% 하락했다. 애널리스트들은 <a href="https://www.benzinga.com/quote/nem/analyst-ratings" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">주가 목표</a>를 하향 조정했다.
4. 테넷 헬스케어(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THC#NYSE">THC</a>)의 주식은 지난주 14.71% 하락했다. 몇몇 헬스케어 주식과 병원 운영자들은 3분기 실적이 감소한 HCA 헬스케어에 동조세 가능성이 있었다.
5. 유니버셜 헬스 서비스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UHS#NYSE">UHS</a>)의 주식은 <a href="https://www.benzinga.com//node/41530333" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">3분기 재무 실적</a>을 발표한 후 지난주 14.33% 하락했다.
6. HCA 헬스케어(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HCA#NYSE">HCA</a>)의 주식은 <a href="https://www.benzinga.com//node/41544243" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">예상보다 저조한 3분기 재무 실적</a>을 발표한 후 12.51% 하락했다. 이 회사는 허리케인 헬렌의 영향이 2025년까지 지속될 것으로 예상하고 있다.
7. 탑빌드(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BLD#NYSE">BLD</a>)의 주식은 허리케인 밀턴의 영향으로 주택 건설 주식이 <a href="https://www.benzinga.com//node/41317881" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">타격을 받은 후</a> 11.48% 하락했다.
8. 칼라일 컴퍼니(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CSL#NYSE">CSL</a>)의 주식은 <a href="https://www.benzinga.com//node/41529849" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">예상보다 저조한 3분기 실적</a> 발표 후 11.45% 하락했다.
9. 테라다인(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TER#NASDAQ">TER</a>)의 주식은 <a href="https://www.benzinga.com//node/41503363" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">3분기 재무 실적</a>을 발표한 후 11.34% 하락했다. 일부 애널리스트들은 <a href="https://www.benzinga.com/quote/ter/analyst-ratings" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">주가 목표</a>를 하향 조정했다.
10. 컴포트 시스템즈 USA(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FIX#NYSE">FIX</a>)의 주식은 <a href="https://www.benzinga.com//node/41530044" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">예상보다 저조한 3분기 매출 실적</a>을 발표한 후 11.27% 하락했다.
추가로 읽어보세요:
<ul>
<li><a href="https://kr.benzinga.com/news/usa/stocks/%ED%85%8C%EC%8A%AC%EB%9D%BC%EC%99%80-%EB%A6%AC-%EC%98%A4%ED%86%A0%EB%8A%94-%EC%A7%80%EB%82%9C%EC%A3%BC-%EC%B5%9C%EA%B3%A0-%EC%84%B1%EA%B3%BC%EB%A5%BC-%EB%B3%B4%EC%97%AC%EC%A4%80-10%EA%B0%9C-%EB%8C%80/" target="_blank" rel="noopener">테슬라와 리 오토는 지난주 최고 성과를 보여준 10개 대형주 중 일부 (10월 21일-10월 25일)</a></li>
</ul>
다른 트레이더들보다 30분 일찍 독점 시장 움직임 뉴스를 받아보세요. 
Benzinga Pro의 14일 무료 체험을 통해 독점 뉴스 기사를 이용할 수 있어 수백만 명의 다른 트레이더보다 먼저 실행 가능한 거래 뉴스를 얻을 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

이들 11개 대형주는 지난주 최고의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요?
<ol>
<li>QXO(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QXO#NASDAQ">QXO</a>)의 주가는 <a href="https://www.benzinga.com//node/39880836" target="_blank" rel="noreferrer noopener">사모 금융 유치</a>를 발표한 이후 33.37% 상승했다.</li>
<li>아반토(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AVTR#NYSE">AVTR</a>)의 주식은 S&amp;P MidCap 400에 편입된다는 발표 이후 지난 주에 21.62% 상승했다. 또한 예상보다 나은 2분기 실적을 발표했다.</li>
<li>유니버셜 헬스 서비스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UHS#NYSE">UHS</a>)는 회사가 예상보다 나은 2분기 실적을 발표하고 <a href="https://www.benzinga.com//node/39942622" target="_blank" rel="noreferrer noopener">2024 회계연도 지침을</a> 상향 조정한 후 주가가 17.73% 상승했다.</li>
<li>맨하탄 어소시에이츠(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MANH#NASDAQ">MANH</a>)의 주가는 예상보다 나은 2분기 재무 결과를 보고한 후 17.02% 상승했다. 몇몇 분석가들은 주식에 대한 가격 <a href="https://www.benzinga.com/quote/MANH/analyst-ratings" target="_blank" rel="noreferrer noopener">예측</a>을 높였다.</li>
<li>몰리나 헬스케어(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>)의 주가는 <a href="https://www.benzinga.com//node/39942485" target="_blank" rel="noreferrer noopener">예상보다 좋은 2분기 실적</a>에 힘입어 15.53% 상승했다.</li>
<li>퍼스트 시티즌스 뱅크셰어스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FCNCA#NASDAQ">FCNCA</a>)의 주가는 회사의 분기 실적이 예상보다 높았음을 보고한 후 15.15% 상승했다.</li>
<li>테넷 헬스케어(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THC#NYSE">THC</a>)는 예상보다 나은 2분기 재무 결과를 보고한 후 주가가 13.02% 상승했으며, 회사는 FY24 지침을 추정치보다 높이고 3분기 지침을 추정치보다 높게 발표했다. 또한 회사는 <a href="https://www.benzinga.com//node/39934114" target="_blank" rel="noreferrer noopener">15억 달러 규모의</a> 자사주 매입을 승인했다고 발표했다.</li>
<li>CBRE 그룹(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CBRE#NYSE">CBRE</a>)은 회사가 2024년 목표를 상향 조정한 후 지난 주 주가가 12.99% 상승했다. 몇몇 분석가들은 주식에 대한 가격 <a href="https://www.benzinga.com/quote/MANH/analyst-ratings" target="_blank" rel="noreferrer noopener">예측</a>을 높였다.</li>
<li>써모 피셔 사이언티픽(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>)의 주가는 지난주 12.63% 상승했다. 이 회사는 연간 전망을 <a href="https://www.benzinga.com//node/39930516" target="_blank" rel="noreferrer noopener">상향 조정</a>했다.</li>
<li>다나허(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>)의 주가는 회사가 예상보다 나은 2분기 실적을 보고한 후 11.30% 상승하여 더 높게 거래되고 있다.</li>
<li>록히드 마틴(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LMT#NYSE">LMT</a>)의 주가는 긍정적인 애널리스트 <a href="https://www.benzinga.com//node/39941283" target="_blank" rel="noreferrer noopener">평가와 강한 2분기 실적</a>에 힘입어 10.72% 상승했다.</li>
</ol>
다음 기사:
<ul>
<li><a href="https://kr.benzinga.com/news/usa/stocks/%ed%8f%ac%eb%93%9c-%ec%8a%a4%ed%85%94%eb%9e%80%ed%8b%b0%ec%8a%a4-%eb%b0%8f-%eb%8d%b8%ec%9d%80-%ec%a7%80%eb%82%9c%ec%a3%bc-%ec%b5%9c%ec%95%85%ec%9d%98-%ec%84%b1%ea%b3%bc%eb%a5%bc-%eb%b3%b4%ec%9d%b8-12/" target="_blank" rel="noopener">포드, 스텔란티스 및 델은 지난주 최악의 성과를 보인 12개 대형주 중 일부 (7월 21일~7월 27일)</a></li>
</ul>
썸네일 제공: 셔터스톡
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

Comments

Tenet Healthcare

뉴스

에 대한 최신 뉴스 Tenet Healthcare (NYSE:THC) 주식

일요일, 11월 24, 2024

토요일, 10월 26, 2024

일요일, 7월 28, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌